Cabaletta Bio, Inc. NASDAQ:CABA

Founder-led company

Cabaletta Bio stock price today

$1.649
-0.64
-27.98%
Financial Health
0
1
2
3
4
5
6
7
8
9

Cabaletta Bio stock price monthly change

-72.21%
month

Cabaletta Bio stock price quarterly change

-72.21%
quarter

Cabaletta Bio stock price yearly change

-90.20%
year

Cabaletta Bio key metrics

Market Cap
112.50M
Enterprise value
103.34M
P/E
-4.49
EV/Sales
N/A
EV/EBITDA
-1.34
Price/Sales
N/A
Price/Book
1.72
PEG ratio
0.12
EPS
-1.72
Revenue
N/A
EBITDA
-84.63M
Income
-76.86M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Cabaletta Bio stock price history

Cabaletta Bio stock forecast

Cabaletta Bio financial statements

Cabaletta Bio, Inc. (NASDAQ:CABA): Profit margin
Jun 2023 0 -14.48M
Sep 2023 0 -16.44M
Dec 2023 4.01M -20.88M -520.85%
Mar 2024 0 -25.04M
Cabaletta Bio, Inc. (NASDAQ:CABA): Analyst Estimates
Sep 2025 0 -32.36M
Oct 2025 0 -33.40M
Dec 2025 0 -29.95M
Mar 2026 0 -32.18M
  • Analysts Price target

  • Financials & Ratios estimates

0%
Yield TTM
Cabaletta Bio, Inc. (NASDAQ:CABA): Payout ratio
Payout ratio 0%
Cabaletta Bio, Inc. (NASDAQ:CABA): Dividend Yield
2019 3.01%
2020
2021
2022
2023
Cabaletta Bio, Inc. (NASDAQ:CABA): Debt to assets
Jun 2023 184637000 10.49M 5.68%
Sep 2023 173287000 12.36M 7.13%
Dec 2023 253650000 17.45M 6.88%
Mar 2024 240457000 18.73M 7.79%
Cabaletta Bio, Inc. (NASDAQ:CABA): Cash Flow
Jun 2023 -11.88M -48.14M 94.25M
Sep 2023 -12.60M -65K 98K
Dec 2023 -16.44M 1.13M 93.04M
Mar 2024 -23.98M -812K 6.85M

Cabaletta Bio alternative data

Cabaletta Bio, Inc. (NASDAQ:CABA): Employee count
Aug 2023 66
Sep 2023 77
Oct 2023 77
Nov 2023 77
Dec 2023 92
Jan 2024 92
Feb 2024 92
Mar 2024 101
Apr 2024 101
May 2024 101
Jun 2024 118
Jul 2024 118

Cabaletta Bio other data

85.87% -14.13%
of CABA is owned by hedge funds
1.84M -18.03M
shares is hold by hedge funds

Cabaletta Bio, Inc. (NASDAQ:CABA): Insider trades (number of shares)
Period Buy Sel
May 2023 0 22000
Jun 2023 0 11000
Jul 2023 0 11000
Aug 2023 0 11000
Sep 2023 0 11000
Oct 2023 0 11000
Nov 2023 0 11000
Dec 2023 0 11000
Jan 2024 0 11000
Transaction Date Insider Security Shares Price per share Total value Source
Option
BINDER GWENDOLYN officer: See Rema.. Stock Option (Right to Buy) 11,000 $1.01 $11,110
Option
BINDER GWENDOLYN officer: See Rema.. Common Stock 11,000 $1.01 $11,110
Sale
BINDER GWENDOLYN officer: See Rema.. Common Stock 10,300 $19.54 $201,211
Sale
BINDER GWENDOLYN officer: See Rema.. Common Stock 700 $20.33 $14,229
Option
BINDER GWENDOLYN officer: See Rema.. Stock Option (Right to Buy) 11,000 $1.01 $11,110
Option
BINDER GWENDOLYN officer: See Rema.. Common Stock 11,000 $1.01 $11,110
Sale
BINDER GWENDOLYN officer: See Rema.. Common Stock 7,868 $21.76 $171,200
Sale
BINDER GWENDOLYN officer: See Rema.. Common Stock 3,132 $22.22 $69,593
Option
BINDER GWENDOLYN officer: See Rema.. Stock Option (Right to Buy) 11,000 $1.01 $11,110
Option
BINDER GWENDOLYN officer: See Rema.. Common Stock 11,000 $1.01 $11,110
Tuesday, 22 October 2024
seekingalpha.com
Wednesday, 25 September 2024
globenewswire.com
Wednesday, 28 August 2024
globenewswire.com
Thursday, 8 August 2024
globenewswire.com
Tuesday, 2 July 2024
globenewswire.com
Friday, 28 June 2024
seekingalpha.com
Friday, 14 June 2024
globenewswire.com
Wednesday, 15 May 2024
globenewswire.com
Monday, 13 May 2024
GlobeNewsWire
Wednesday, 31 January 2024
Seeking Alpha
Sunday, 10 December 2023
Seeking Alpha
Tuesday, 28 November 2023
Market Watch
Monday, 30 October 2023
GlobeNewsWire
Monday, 9 October 2023
Zacks Investment Research
Monday, 25 September 2023
Zacks Investment Research
Tuesday, 19 September 2023
GlobeNewsWire
Seeking Alpha
Friday, 8 September 2023
Zacks Investment Research
Thursday, 31 August 2023
InvestorPlace
Wednesday, 30 August 2023
GlobeNewsWire
Wednesday, 23 August 2023
Zacks Investment Research
Tuesday, 15 August 2023
Zacks Investment Research
Tuesday, 18 July 2023
The Motley Fool
Wednesday, 21 June 2023
InvestorPlace
Sunday, 21 May 2023
CNBC
Tuesday, 2 May 2023
GlobeNewsWire
Thursday, 13 April 2023
GlobeNewsWire
Friday, 31 March 2023
InvestorPlace
Tuesday, 28 February 2023
GlobeNewsWire
Monday, 6 February 2023
Zacks Investment Research
  • What's the price of Cabaletta Bio stock today?

    One share of Cabaletta Bio stock can currently be purchased for approximately $1.65.

  • When is Cabaletta Bio's next earnings date?

    Unfortunately, Cabaletta Bio's (CABA) next earnings date is currently unknown.

  • Does Cabaletta Bio pay dividends?

    No, Cabaletta Bio does not pay dividends.

  • How much money does Cabaletta Bio make?

    Cabaletta Bio has a market capitalization of 112.50M.

  • What is Cabaletta Bio's stock symbol?

    Cabaletta Bio, Inc. is traded on the NASDAQ under the ticker symbol "CABA".

  • What is Cabaletta Bio's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Cabaletta Bio?

    Shares of Cabaletta Bio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Cabaletta Bio's key executives?

    Cabaletta Bio's management team includes the following people:

    • Dr. Steven A. Nichtberger Co-Founder, Chairman, Chief Executive Officer & Pres(age: 64, pay: $871,160)
    • Dr. David J. Chang M.D., M.P.H. Chief Medical Officer(age: 62, pay: $638,630)
    • Dr. Gwendolyn K. Binder Executive Vice President of Science & Technology(age: 50, pay: $625,130)
  • Is Cabaletta Bio founder-led company?

    Yes, Cabaletta Bio is a company led by its founder Dr. Steven A. Nichtberger.

  • How many employees does Cabaletta Bio have?

    As Jul 2024, Cabaletta Bio employs 118 workers, which is 17% more then previous quarter.

  • When Cabaletta Bio went public?

    Cabaletta Bio, Inc. is publicly traded company for more then 5 years since IPO on 25 Oct 2019.

  • What is Cabaletta Bio's official website?

    The official website for Cabaletta Bio is cabalettabio.com.

  • Where are Cabaletta Bio's headquarters?

    Cabaletta Bio is headquartered at 2929 Arch Street, Philadelphia, PA.

  • How can i contact Cabaletta Bio?

    Cabaletta Bio's mailing address is 2929 Arch Street, Philadelphia, PA and company can be reached via phone at +267 7593100.

Cabaletta Bio company profile:

Cabaletta Bio, Inc.

cabalettabio.com
Exchange:

NASDAQ

Full time employees:

136

Industry:

Biotechnology

Sector:

Healthcare

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

2929 Arch Street
Philadelphia, PA 19104

CIK: 0001759138
ISIN: US12674W1099
CUSIP: 12674W109